Skip to main content

Table 1 Baseline patient demographic and disease characteristics of the study population

From: The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major

Characteristics Mesenchymal patients Non-mesenchymal patients P value
Number (%) 83 131
Age (years), median (P25–P75) 15.37 (11.77–19) 12.89 (9.22–18.4) 0.023
Patient sex, n (%) Male 54 (65.1%) 74 (56.5%) 0.213
Female 29 (34.9%) 57 (43.5%)
Donor sex, n (%) Male 41 (51.3%) 51 (42.9%) 0.244
Female 39 (48.7%) 68 (57.1%)
Sex match status, n (%) Sex-mismatched 48 (60%) 54 (45.4%) 0.043
Sex-matched 32 (40%) 65 (54.6%)
ABO match status, n (%) ABO-mismatched 30 (37.5%) 46 (37.4%) 0.988
ABO-matched 50 (62.5%) 77 (62.6%)
Survival status, n (%) Alive 60 (72.3%) 86 (65.6%) 0.309
Dead 23 (27.7%) 45 (34.4%)
Source of HSCT, n (%) BM 29 (34.9%) 52 (39.7%) 0.485
PB 54 (65.1%) 79 (60.3%)
Acute GvHD, n (%) No 40 (48.2%) 74 (56.5%) 0.236
Yes 43 (51.8%) 57 (43.5%)
Chronic GvHD, n (%) No 53 (63.9%) 81 (61.8%) 0.766
Yes 30 (36.1%) 50 (38.2%)
Stem cell number in grafts WBC (× 108/kg), median (P25–P75) 8.12 (5.79–10.05) 8.41 (6.27–9.32) 0.758
MNC (× 108/kg), median (P25–P75) 7.03 (3–8.07) 6.80 (3.5–8.36) 0.317
CD3 cell (× 106/kg), median (P25–P75) 213.22 (53–339) 221.05 (75.8–314.8) 0.836
CD34 cell (× 106/kg), median (P25–P75) 3.9 (2.5–6.1) 3.4 (2.5–7.4) 0.712
  1. GVHD graft-versus-host disease, HSCT hematopoietic stem cell transplantation, MNC mononuclear cell, WBC white blood cells, BM bone marrow, PB peripheral blood